Steven Silver
Stock Analyst at Argus Research
(3.81)
# 1,934
Out of 4,520 analysts
23
Total ratings
80%
Success rate
23.1%
Average return
Main Sectors:
Stocks Rated by Steven Silver
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPCX Space Exploration Technologies | Initiated Coverage: Hold | n/a | $123.99 | - | 1 | Jun 25, 2026 | |
| CVS CVS Health | Maintained: Buy | $90 → $104 | $107.47 | -3.23% | 4 | May 13, 2026 | |
| BAX Baxter International | Maintained: Hold | n/a | $22.61 | - | 4 | May 8, 2026 | |
| CAH Cardinal Health | Maintained: Buy | $189 → $248 | $228.52 | +8.52% | 4 | May 5, 2026 | |
| DXCM DexCom | Maintained: Buy | $100 → $90 | $76.65 | +17.42% | 2 | Nov 7, 2025 | |
| ITGR Integer Holdings | Downgraded: Hold | n/a | $95.42 | - | 2 | Oct 24, 2025 | |
| TZOO Travelzoo | Reiterated: Buy | $19 | $10.94 | n/a | 1 | May 11, 2022 | |
| THC Tenet Healthcare | Downgraded: Hold | n/a | $194.91 | n/a | 1 | Jun 13, 2014 | |
| ALNY Alnylam Pharmaceuticals | Rated: Buy | n/a | $267.47 | n/a | 2 | Jan 27, 2014 | |
| GILD Gilead Sciences | Maintained: Buy | $94 | $134.28 | n/a | 1 | Dec 9, 2013 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $15.01 | n/a | 1 | Oct 22, 2010 |
Space Exploration Technologies
Jun 25, 2026
Initiated Coverage: Hold
Price Target: n/a
Current: $123.99
Upside: -
CVS Health
May 13, 2026
Maintained: Buy
Price Target: $90 → $104
Current: $107.47
Upside: -3.23%
Baxter International
May 8, 2026
Maintained: Hold
Price Target: n/a
Current: $22.61
Upside: -
Cardinal Health
May 5, 2026
Maintained: Buy
Price Target: $189 → $248
Current: $228.52
Upside: +8.52%
DexCom
Nov 7, 2025
Maintained: Buy
Price Target: $100 → $90
Current: $76.65
Upside: +17.42%
Integer Holdings
Oct 24, 2025
Downgraded: Hold
Price Target: n/a
Current: $95.42
Upside: -
Travelzoo
May 11, 2022
Reiterated: Buy
Price Target: $19
Current: $10.94
Upside: n/a
Tenet Healthcare
Jun 13, 2014
Downgraded: Hold
Price Target: n/a
Current: $194.91
Upside: n/a
Alnylam Pharmaceuticals
Jan 27, 2014
Rated: Buy
Price Target: n/a
Current: $267.47
Upside: n/a
Gilead Sciences
Dec 9, 2013
Maintained: Buy
Price Target: $94
Current: $134.28
Upside: n/a
Oct 22, 2010
Maintained: Buy
Price Target: n/a
Current: $15.01
Upside: n/a